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Prostaglandin E2 (PGE2) induces bone formation in stress-bearing bones. The mandible, a stress-bearing bone, is loaded daily during
mastication. The aim of this study was to determine if PGE2 delivered locally to the mandible over 20 days enhances alveolar bone
deposition. In 18 Lewis rats, controlled-release pellets containing PGE2 were implanted on the buccal aspect on the left-hand side of the
mandible, mesial to the root of the first molar. Controlled-release pellets locally delivered 0.1, 0.05, or 0.025 mg/day of PGE2. The right side
of the mandible was used as a matched control for each animal. Six sham-treated animals were implanted with a placebo pellet. On days 7
and 19, animals were injected with the bone markers tetracycline and calcein, respectively. On day 21, animals were sacrificed and
undecalcified tissues obtained for morphometrical analysis. Morphometrical measurements were analyzed by paired t test to determine
differences between the matched samples and one-way ANOVA to compare the different treatment groups. A significant increase in alveolar
bone area was observed in mandibles treated with 0.1 and 0.05 mg/day when compared with matched controls and the placebo group. This
was accompanied by a significant increase in alveolar bone height and width. The proportions of double-labeled surface (dLS), the mineral
apposition rate (MAR), and bone formation rate (BFR) were significantly increased in mandibles treated with the two higher doses of PGE2.
The proportion of resorptive surface (RS) was significantly reduced in these two groups. It is concluded that PGE2 induces alveolar bone
formation in the mandible when locally delivered at a dose of 0.1 or 0.05 mg/day for 20 days.
D 2004 Elsevier Inc. All rights reserved.
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Bone is a highly dynamic tissue undergoing continuous
turn over under the influence of the local environment.
Prostaglandin E2 (PGE2), a derivative of arachidonic acid
[5], induces periosteal and endocortical bone formation,
principally by stimulating local osteoprogenitor cells on the
adjacent endocortical surface [3,21]. Recently, studies have
also shown that the response of bone cells to PGE2 is related
to the dose and route of administration [3,16].
The anabolic effect of PGE2 demonstrated in long bones
may also occur in the mandible. Particularly as local8756-3282/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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enhance the formation of mandibular alveolar bone,
reorganization of adjacent cells in the periodontal ligament
and cementum formation [11,13,18]. The positive effect of
PGE2 on bone deposition has been reported with doses as
low as 1 mg/kg per day delivered subcutaneously into
different animal models over extended periods of time
[1,6,9,20]. In load-bearing bones, PGE2 has an anabolic
effect when administered either systemically or locally [7].
In addition, the dose of PGE2 required to prevent bone loss
in ovariectomized rats may be reduced if PGE2 treatment is
accompanied with exercise [15]. As the mandible
bexercisesQ through mastication, it is hypothesized that
PGE2 stimulates higher rates of alveolar bone deposition
when delivered locally to the mandible. Bone deposition
stimulated by an external agent (i.e., PGE2) may be
extended for up to 20 days, which is the duration of the1361–1368
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by cultured progenitor osteoblasts to differentiate and
mature [2], even though the remodeling cycle in the
mandibular alveolar bone appears to run faster [19].
Therefore, the aim of this study is to determine if PGE2
locally delivered to the mandible over 20 days stimulates
alveolar bone formation in the rat mandible.Materials and methods
Twenty-four, 12-week-old, female Lewis rats were
obtained from the Animal Resource Centre at the University
of Western Australia. The animals were weighed at the
beginning and at the end of the experiment. Ethical approval
for the study was obtained from the University of Queens-
land Animal Experimentation Ethics Committee (DENT/
046/02/NHMRC).
Pellet implantation
The animals were divided into four groups for treatment
with either PGE2 or placebo. Each group was composed by
six animals. A PGE2-controlled release pellet or a placebo
pellet (Innovative Research of America, Toledo, OH) was
implanted on the buccal aspect on the left mandible adjacent
to the mesial root of the first molar. For implantation of
pellets, rats were anaesthetized with a single intraperitoneal
injection of Xylazil/Ketamine (100 mg/kg). An incision of
approximately 0.5 cm was made at the lower border of the
mandible, tissue reflected to expose the masseter muscle that
was displaced distally to reveal the alveolar bone covering the
roots of the first molar. The surgical site was sutured with silk
(3/0) ligature following placement of the pellet. The
experimental animals were implanted with a controlled-
release pellet delivering a dose of 0.1, 0.05, or 0.025 mg of
PGE2 per day over a 20-day period. In the sham-treated
group, a placebo pellet (Innovative Research of America)
containing the carrier, but no PGE2, was implanted.
Seven days following pellet insertion, rats were injected
intraperitoneally with tetracycline hydrochloride (SIGMAT-
3383, 30 mg/kg) to mark sites of bone formation. At day 19
post-pellet implantation, animals were injected with a
second bone marker calcein (SIGMA C-0875 10 mg/kg).
Animals were monitored during the experimental time for
adverse reactions such as redness on paws or ears, weak-
ness, or inflammation in the area of pellet implantation. All
rats were maintained under the same conditions and
consumed a normal diet.
Twenty-one days following pellet implantation, intra-
cardiac perfusion was performed with fixative (4% Paraf-
ormaldehyde in 0.1 M phosphate-buffered saline (PBS)),
and the rats sacrificed by exsanguination. Mandibles were
harvested and placed into the same fixative for 4 h. The
mandibles were separated into left (experimental) and right
(nonexperimental) sides.Before implantation, pellets were tested for PGE2 release.
Pellets containing placebo and the three doses of PGE2 were
incubated in culture media (DMEM; GIBCO Cat No.
12100-061), and the supernatant collected at days 3, 5, 7,
and 10. The concentration of PGE2 in the supernatant was
determined by ELISA (Cayman Chemical, Ann Arbor MI,
USA, Cat No. 514010).
Hard tissue sections
Hemi-mandibles were embedded in acrylic resin (LR
White medium grade, The London Resin Company, UK).
Undecalcified transverse serial sections (90–100 Am) were
cut perpendicular to the occlusal plane, in a bucco-lingual
direction, using a hard tissue microtome (Leitz saw micro-
tome 1600, Oberkochen-Germany). Transverse bucco-lin-
gual sections of the mesial root of the first molar tooth were
obtained and mounted on glass slides. Hard tissue sections
were standardized so that each section included the total
length of the crown, total length of the root (including the
pulp chamber from the crown to the apex), alveolar bone on
the buccal and the lingual aspects, and crypt of the incisor
tooth including the lower margin (Fig. 1). One standardized
section per hemi-mandible was obtained.
Mounted hard tissue sections were photographed using a
digital camera (Nikon Coolpix 995, Japan) mounted on a
polarized microscope (Olympus, Tokyo, Japan). Photogra-
phy was performed at a magnification of 2.5. Images were
transferred to a computer (Pentium III, 1 GHz processor,
256 Mb RAM, 32 Mb video card) and analyzed using
computerized image analyzer software (Scion image Beta
4.0.2, Scion Corp, Maryland, USA), precalibrated with a 1-
mm scalar taken under the same conditions. Undecalcified
tissue sections from each group were stained with hema-
toxylin and eosin (H&E) to determine if an inflammatory
reaction was evident in tissues adjacent to the site of pellet
implantation.
Bone histomorphometry
For this purpose, a vertical line was drawn along the long
axis of the first molar, from the center of the occlusal surface
of the crown (bucco-lingual) to the center of the aperture at
the root apex. A horizontal line, perpendicular to the long
axis and tangential to the bone margin on the superior aspect
of the bone crypt of the incisor, was drawn on the digitized
picture (Fig. 1). The area of alveolar bone measured was
buccal to the vertical line and superior to the horizontal line
on the buccal aspect of the mesial root of the lower first
molar. Height and width of the alveolar bone were also
determined at the same area. Alveolar bone height was
determined by measuring the distance from the horizontal
line to the tip of the alveolar bone just beneath the oral
epithelium (Fig. 1, line c). Alveolar bone width was
measured at two points. The first measurement was in the
mid region of the alveolar bone area, taking as landmark the
Fig. 1. Polarized picture of a section at the mesial root of the first molar
tooth showing the buccal aspect (Buc) of the alveolar bone area measured
(arrow) delimited by the longitudinal axis of the molar (a), the tangent to
the incisor chamber (b), the buccal border of the alveolar bone, and the
internal border of the alveolar bone limiting with the periodontal ligament
(PDL). The site of alveolar height measurement (c) and the sites of
alveolar width measurements at the mid-region (d) and at the apical
region (e) are also shown. (Lin) Lingual aspect; (In) Incisor. Magnifica-
tion: 2.5.
Fig. 2. Apical area of the alveolar bone from a mandible stimulated with placebo
wider and more continuous band between the tetracycline (yellow) and the calcein
of resorptive surface (arrows) are observed in the placebo-stimulated mandible. M
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between the internal (facing the periodontal ligament) and
the external (facing the periosteum) borders of the alveolar
bone (Awa) (Fig. 1, line d). The second measurement was in
the apical region of the alveolar bone area. The distance was
measured from the point where the long axis of the tooth
intersects with the base of the alveolar socket to the external
border of the alveolar bone (Awp) (Fig. 1, line e). Both
alveolar width measurements were perpendicular to the long
axis of the tooth.
Fluorescent bone markers
To determine the distribution of the bone markers on the
buccal aspect of the first molar root, sections were observed
using ultraviolet fluorescence microscopy (Olympus BX60).
Digitized pictures at 2.5 magnification were taken of each
sample (Nikon Coolpix995). The buccal region used for
measurements on the digitized images was as described
above. The perimeter of the surface labeled by the two bone
markers, the distance between the double labeling, and the
perimeter of the resorptive lacunae were measured on the
external and the internal surfaces of the alveolar bone on the
buccal aspect of the mesial root (Fig. 2). These measure-
ments were used to determine indices of bone remodeling.
Hard tissue sections from mandibles not injected with
tetracycline were used as negative controls.
Bone remodeling indices
Four histomorphometric indices were used in this study
to analyze bone biopsy samples [4,12]. The proportion of
the double-labeled surface (dLS) was determined by(A) and from another mandible stimulated with 0.1 mg/day of PGE2 (B). A
(green) lines is observed in the PGE2-stimulated mandible. Higher numbers
agnification: 40.
Fig. 3. Histological section stained with H&E showing the alveolar bone
(A) at the buccal aspect of the first molar root. Several blood vessels are
G.O. Ramirez-Yan˜ez et al. / Bone 35 (2004) 1361–13681364dividing the perimeter of alveolar surface labeled by the two
bone markers over the total perimeter of the measured area
and expressed as percentage. Mineral apposition rate
(MAR) was calculated by dividing the distance between
the two fluorescent labels by the time between the
application of the two bone markers (12 days). MAR was
expressed as Am/day. Bone formation rate (BFR) was
calculated by multiplying the perimeter of dLS times the
MAR and expressed in Am2/day. The last index used was
the proportion of resorptive surface (RS). It was determined
by dividing the sum of the perimeters of the resorptive
lacunae by the total perimeter of the measured area and
expressed as a percentage.
Data analysis
Each measurement was performed twice on different days
(gap of 7 days) by the same operator. The data from both
measurements were analyzed by Spearman correlation test to
determine the level of agreement between them. A high
agreement (r N 0.95) was observed between the two sets of
measurements. An average from both sets of measurements
was used for analysis. The data obtained from the PGE2- and
placebo-stimulated hemi-mandibles were compared with
their matched nonexperimental hemi-mandibles using paired
t test. One-way analysis of variance (ANOVA) was used to
determine statistical differences between the nonexperimen-
tal sides, PGE2, and sham-treated groups.
observed (arrows) in the alveolar bone, but no inflammatory infiltrate is
observed throughout the section. (B) Buccal side; (PDL) Periodontal
ligament; (C) Cementum.
Results
The animals showed neither discomfort nor adverse
reactions to the carrier or drug contained in the pellet over
the duration of the experiment. All animals gained weight
over the experimental period. The average weight at the
beginning was 204.8 g (F2.07 SD), and just before
euthanasia, 233.2 g (F3.11 SD). ELISA for testing pellet
release showed a steady release of PGE2 into themedia for the
testing periods (data not shown). Thus, constant daily release
of PGE2 was confirmed from the controlled-release pellets.
Alveolar bone area
Histological sections stained with H&E demonstrated no
inflammatory cells in the alveolar bone on the buccal aspect
of the first molar or in the surrounding tissues (Fig. 3). The
area of bone on the buccal aspect of the first molar was
significantly increased (P b 0.05) when both placebo and
PGE2-containing pellets were implanted (Fig. 4A). ANOVA
showed that the area of alveolar bone was significantly
increased in animals where doses of 0.1 and 0.05 mg/day
were locally released during the 20-day experimental period
(P b 0.005) compared with the placebo group. No
significant difference in bone area was observed between
the placebo and 0.025 mg/day PGE2 group. The lowestincrease in buccal alveolar bone area was observed in the
0.025 mg/day PGE2 group (Fig. 4A).
Significant differences were found in the height and the
width of the alveolar bone within different treatment groups
when compared with the matched controls (P b 0.05).
However, when both Awa and Awp were compared by
ANOVA, no significant differences were present between
the different groups of treatment, although the highest
values were noted for both measurements on those
mandibles stimulated with the highest doses of PGE2 (Figs.
4B and C). This was not the case for alveolar height, where
significantly higher values were found for those mandibles
treated with the two higher doses of PGE2 compared with
the placebo (P b 0.05). The lowest dose of PGE2 showed
similar values to that of the placebo-treated group.
Bone remodeling indices
There was a significant increase in the proportion of dLS
on the experimental side compared with the nonexperimen-
tal side (P b 0.005). Nevertheless, ANOVA showed that the
proportions of dLS were significantly higher (P b 0.001)
when the implanted pellet released a dose of 0.1 or 0.05 mg/
day of PGE2 over 20 days compared with the placebo-
Fig. 4. (A) Alveolar bone areas from those mandibles stimulated with the two highest doses (0.1 and 0.05 mg/day) of PGE2 show significant higher values (*)
than those stimulated either with placebo or 0.025 mg/day of PGE2. Similar results are shown in the alveolar bone height (B). A direct relationship between the
dose of PGE2 and the values for the alveolar bone widths (mid and apical regions) is observed (C and D), although there are no significant differences between
the different groups of treatment. Results from the mandibles opposite to the site of stimulation used as matched controls (Non-Exp) are shown as the mean of
the different groups of treatment. Mean and SEM are shown.
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significantly lower in the alveolar bone of those mandibles
stimulated with 0.025 mg/day of PGE2 compared with
placebo (P b 0.05).Fig. 5. (A) Double-labeled surface (dLS) by tetracycline and calcein is significantly
0.05 mg/day of PGE2, whereas the resorptive surface (RS) is significantly reduced
bone formation rate (BFR) are also significantly increased when the mandibles a
Mean and SEM are shown.A significant decrease in the proportion of RS was
observed on the experimental side compared with the
nonexperimental side in the 0.1 and 0.05 mg/day PGE2
groups (P b 0.01), but not in those treated with 0.025 mg/(*) higher in the alveolar bone from the mandibles stimulated with 0.1 and
in the same groups of treatment (B). Mineral appositional rate (MAR) and
re stimulated with the two highest doses of PGE2 (C and D, respectively).
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proportion of RS in the alveolar bone was significantly
lower in those mandibles treated with 0.1 and 0.05 mg/day
compared with the placebo-treated group (P b 0.005) (Fig.
5A). When the data from the placebo- and 0.025 mg/day of
PGE2-treated mandibles were compared, no significant
difference was observed (P N 0.05).
Mineral appositional rate, calculated as the amount of
bone (Am) mineralized per day during the experimental
period, showed that there was a significant increase in MAR
in the alveolar bone of those animals treated with PGE2.
This significant difference was higher in those animals
treated with 0.1 and 0.05 mg/day of PGE2 (P b 0.005) when
compared with matched controls, than in those animals
treated with 0.025 mg/day of PGE2 (P b 0.05). No
significant difference was observed for this index in the
animals implanted with a placebo pellet (P N 0.05). When
data from the experimental sides were compared byANOVA
(Fig. 5B), a significantly higher MAR occurred in man-
dibles stimulated with 0.1 and 0.05 mg/day of PGE2
compared with those stimulated with placebo (P b 0.05).
No significant differences in MAR were recorded between
mandibles treated with placebo and those treated with 0.025
mg/day of PGE2, even though a slight reduction in MAR
was noted in those animals stimulated with the lowest dose
of PGE2 (Fig. 5B).
BFR index analyzed by paired t test showed a significant
increase in BFR during the experimental period when the
mandibles were stimulated either with placebo or PGE2.
ANOVA reported significant higher values in BFR in those
animals treated with 0.1 and 0.05 mg/day of PGE2
compared with those treated with placebo (P b 0.001)
(Fig. 5C). The lowest value in BFR was observed in those
mandibles treated with 0.025 mg/day of PGE2 (Fig. 5C),
and there was no significant difference in BFR between this
group and the placebo-treated group (P N 0.05).Discussion
The results from the present study have shown that PGE2
locally delivered adjacent to the mandible over a 20-day
period induced alveolar bone formation, and this effect may
be produced with doses as low as 0.05 mg/day. Prostaglan-
din E2 is known to stimulate bone formation in long bones
[3,6,7], and the dose required to produce this positive effect
may be as low as 0.3 mg/kg per day in load-bearing bones
[15]. The animals used in this experiment weighed about
200 g. If the dose locally delivered to the mandible is
associated with the animals’ weight, 0.1 and 0.05 mg
correspond to 0.5 and 0.25 mg/kg applied daily. In this
context, the dose used in this experiment may be similar to
that proposed for stimulating bone formation in load-bearing
bones [13]. As the mandible exercises through mastication,
low doses of PGE2 may be used to stimulate bone formation
when no pathological conditions are present. Thus, doses aslow as 0.25 mg/kg per day applied locally for a 20-day
period may be used to stimulate bone formation in the
alveolar bone.
Morphometrical analysis reported an increase in the
alveolar bone area following pellet implantation. This may
be the result of a stimulatory effect induced by the pellet
carrier (the contents were not released by the pellet
manufacturer) or as a response to inflammation associated
with the procedure. The authors propose the response is
related to the pellet carrier rather than to inflammation, as
the surgery was atraumatic and no postsurgical inflamma-
tion or irritation was observed. Inflammation associated
with pellet surgery is more likely to be located in the soft
tissue rather than in the mineralized tissues. However, the
area of alveolar bone at the buccal aspect adjacent to the
mesial root of the first molar in the mandible of those
animals treated with the two highest doses of PGE2 (0.1 and
0.05 mg/day) was significant greater than that observed in
animals treated with 0.025 PGE2 mg/day or placebo. These
results showed that PGE2 induced localized alveolar bone
formation in the mandible similar to that observed in long
bones [3,6,7], and were consistent with the effect of PGE1
in the mandible [10,11,14,17]. It should be noted that the
mandible was not injured during pellet implantation, there
was no evidence of inflammation in the soft tissues
following healing and at the end of the experimental period.
In addition, no inflammatory cells were evident in histo-
logical tissue sections. Thus, in this study, exogenous PGE2
stimulated alveolar bone formation in normal physiological
conditions. However, in the presence of trauma or inflam-
mation, localized and long-term application of low dose
PGE2 may not promote bone formation but rather bone
resorption and tissue loss.
An increase in alveolar bone area is the result of an
increase in the dimensions of the bone on the buccal aspect.
An increase in alveolar bone area in the buccal aspect on the
experimental side was observed in all animals after pellet
implantation. This is the result of significant increases in the
height and the width of the alveolar bone on the side of
pellet implantation when compared with their matched
controls. Nevertheless, comparing the different groups of
treatment by ANOVA, significant higher alveolar bone areas
were observed at the buccal aspect in those mandibles
stimulated with the two highest doses of PGE2. Alveolar
bone height was significantly greater in those animals
treated with the two higher doses of PGE2 compared with
those treated with 0.025 PGE2 mg/day or placebo. Although
there were no significant differences in width of the alveolar
bone (Awa and Awp) between those animals treated with
PGE2 and those treated with placebo, a wider bone was
observed in those animals treated with the higher doses of
PGE2 (0.1 and 0.05 mg/day). Thus, the significantly higher
alveolar bone areas found in the buccal aspect of those
animals treated with the two higher doses of PGE2 results
from a significant increase in the height of the alveolar bone
associated to a wider alveolar bone. This suggests that PGE2
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height is affected more than alveolar bone width, which
means bone turnover may be affected at different sites.
Although this study showed that when PGE2 was locally
applied to the mandible, it had a positive effect on alveolar
bone height and area, further studies are required to
determine if this reaction may be further developed for a
therapeutic application.
The bone remodeling cycle is composed of two phases,
bone deposition and bone resorption, which maintain bone
turnover [12]. The duration of the remodeling cycle in the
mandibular alveolar bone is shorter than in the long bones
[18]. In the long bones, the remodeling cycle is 20–30 days
[7], whereas in the alveolar bone, it is 6 days plus a 5-day
resting period [17]. The experimental period in this study
extended for 20 days, implying that two remodeling cycles
occurred. Bone remodeling indices showed that the two
higher doses of PGE2 increased MAR and BFR compared
with the placebo, and thus, more mineralized tissue was
deposited during the experimental period. This effect is
associated with a decrease in the proportion of RS. The
combined effect of PGE2-stimulated bone deposition and
decreased bone resorption leads to the higher proportion of
dLS observed when the mandibles were treated with 0.1 and
0.05 mg/day of PGE2. A significant increase in the
proportion of dLS associated with a significant decrease in
the proportion of RS suggests that PGE2 has an effect on
both sides of the remodeling cycle, shifting the cycle to
increased bone formation [14]. Though these results are not
conclusive for a role of PGE2 on the remodeling cycle and
on the bone cells, it may be hypothesized that PGE2 affects
the differentiation process and physiology of osteoblasts and
osteoclasts, and so affects the remodeling rates.
Bone modeling is defined as the process by which the
size or the shape of bone is changed in response to either
intrinsic or extrinsic influences [4]. Whereas, bone remod-
eling consists of the removal and replacement of bone, and
does not affect size or shape of that particular remodeled
area [4,12]. This study showed that PGE2 locally delivered
on the mandible at doses of 0.1 and 0.05 mg/day produced
an increase in the size of the alveolar bone after 20 days of
treatment. In other words, the effect of PGE2 on the alveolar
bone in the mandible produced a change in the size of this
bone by affecting its dimensions. Furthermore, PGE2
appears to affect bone turnover at different sites. The effect
of PGE2 on the alveolar bone may be described as a
modeling-dependent bone gain, which may be due to new
bone formation directly on the bone surface and at different
locations [15]. This modeling-dependent bone gain stimu-
lated by PGE2 has been described previously in long bones
[3], and this study showed that it also occurs in the
mandible. Nevertheless, the eicosanoid may not be only
responsible for these results as the effect of PGE2 low doses
on new bone formation at different surface locations has
been associated to an interaction between loading (local
tissue strains) and drug treatment [13].Conclusions
The present study demonstrates that PGE2 induced
alveolar bone formation when it is locally delivered to the
mandible over 20 days at doses of 0.1 and 0.05 mg/day. The
results shown may be due to an action of PGE2 on the
remodeling cycle, increasing bone deposition while reduc-
ing bone resorption, as well as stimulating new bone
formation on the bone surface. This effect of PGE2 appears
to be associated with local tissue strains. Further studies are
necessary to understand the action of PGE2 on the bone
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